OncoMatch/Clinical Trials/NCT06733948
ChemoRT With and Without Dental Stent for Taste Protection in NPC Patients
Is NCT06733948 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Dental stent for nasopharyngeal carcinoma.
Treatment: Dental stent — Primary objective: Evaluate and compare incidence of acute and long-term taste dysfunction in chemoradiation plus dental stent group vs. chemoradiation group, using objective-measured taste strip test, and patient-reported taste ability and toxicity. Secondary objectives: 1. Evaluate and compare incidence of acute and long-term toxicities (excluding taste) and patient-reported quality of life between chemoradiation plus dental stent group and chemoradiation group. 2. Evaluate and compare tumor response, overall survival, and failure-free survival between chemoradiation plus dental stent group and chemoradiation group. 3. Analyze dosimetric parameters of taste bud bearing tongue mucosa, ipsilateral/ contralateral parotid and submandibular glands extracted from RT plans and correlate with taste impair
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage TXN0, TXN1, TXN2, TXN3
Tumours staged as T1-4N+/TxN0-3. No sign of distant metastasis (M0).
Performance status
KARNOFSKY OR ECOG 70–1
Karnofsky Performance Status ≥ 70 or ECOG < 2
Prior therapy
Cannot have received: radiation therapy
Exception: except for non-melanomatous skin cancers outside the intended RT treatment area
Received RT previously (except for non-melanomatous skin cancers outside the intended RT treatment area)
Cannot have received: surgery
Exception: except diagnostic
Patients who received previous surgery (except diagnostic) for the primary tumours or lymph nodes or history of glossectomy
Cannot have received: chemotherapy
Patients who received previous...chemotherapy for the primary tumours or lymph nodes
Lab requirements
Blood counts
≥ 3 × 10^9/L leucocytes; ≥ 1.5 × 10^9/L neutrophils; ≥ 9 g/dL haemoglobin; ≥ 100 × 10^9/L platelets
Kidney function
Creatinine clearance ≥60 mL/min
Liver function
ALT and AST < 1.5x ULN; ALP < 2.5x ULN; Bilirubin < ULN
Adequate bone marrow function by peripheral blood counts... Normal liver function... Renal function: Creatinine clearance at ≥60 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify